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Abstract: Genome-wide association studies (GWAS) have identified SNPs associated with breast cancer. However, they offer limited 
insights about the biological mechanisms by which SNPs confer risk. We investigated the association of GWAS information with a 
major oncogenic pathway in breast cancer, the Notch signaling pathway. We first identified 385 SNPs and 150 genes associated with 
risk for breast cancer by mining data from 41 GWAS. We then investigated their expression, along with 32 genes involved in the Notch 
signaling pathway using two publicly available gene expression data sets from the Caucasian (42 cases and 143 controls) and Asian 
(43 cases and 43 controls) populations. Pathway prediction and network modeling confirmed that Notch receptors and genes involved 
in the Notch signaling pathway interact with genes containing SNPs associated with risk for breast cancer. Additionally, we identified 
other SNP-associated biological pathways relevant to breast cancer, including the P53, apoptosis and MAP kinase pathways.
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Introduction
The  lifetime  risk  of  developing  breast  cancer  is 
about one in eight for women, with around 192,370 
new invasive cases, 62,280 new in situ cases being 
  diagnosed  and  40,170  deaths  in  the  United  States 
each year.1 Breast cancer is the second leading cause 
of cancer death among women in the US. While major 
inroads have been made in reducing mortality rates 
due  to  increased  screening,  digital  mammography, 
specialized care, and the widespread use of therapeu-
tic agents such as aromatase inhibitors, trastuzumab 
and others, defining the genetic architecture of breast 
cancer remains an important long-term goal for the 
development of more effective therapeutic strategies 
and early interventions. Recent advances in microar-
ray  technology  and  reduction  in  genotyping  costs 
have made possible genome-wide association studies 
to identify genetic variants associated with risk for 
breast cancer.2–6 Although these studies are providing 
valuable clues about the broad patterns of genetic sus-
ceptibility to breast cancer, the ultimate goal of SNP 
and gene discovery is to identify and characterize the 
biological pathways and the molecular mechanisms 
underlying the disease. This is especially important 
in breast cancer, a group of biologically and geneti-
cally heterogeneous diseases with distinct oncogenic 
pathways and therapeutic targets. To date, there is 
little information associating GWAS data to known 
oncogenetic pathways involved in breast cancer. This 
knowledge gap is hindering translation of discoveries 
from GWAS into clinical practice to develop clini-
cally useful genetic tests as well as early therapeutic 
interventions and new targeted drugs.
The  objective  of  this  study  was  to  investigate 
the  association  of  GWAS  information  with  the 
Notch   signaling pathway. The rationale for choos-
ing the Notch signaling pathway in this study was 
that apart from its involvement in breast cancer, the 
Notch   signaling pathway is involved in many types 
of cancer including breast cancer, lung cancer, neu-
roblastomas, skin cancer, cervical cancer, and pros-
tate cancer.7 However, it is less well characterized 
compared to other biological pathways involved in 
breast cancer such as the estrogen, kinase, apopto-
sis and P53   pathways which are enriched with SNPs 
associated with risk for breast cancer. Consequently, 
association of GWAS information with the Notch sig-
naling pathway may provide proof of concept that this 
approach could work and provide insights about the 
putative functional bridges between GWAS informa-
tion and biological pathways that are less character-
ized and may not contain genes harboring mutations 
or SNPs associated with cancer. The Notch signaling 
pathway  is  extremely  contextual-dependent,  mean-
ing that crosstalk and interaction with other pathways 
including  those  enriched  by  SNPs  associated  with 
risk  for  breast  cancer  would  be  very  important  in 
determining outcomes. With the exception of T-ALL 
(T-cell acute lymphoblastic leukemia),7 there are very 
few instances where mutations have been detected in 
solid tumors in Notch pathway genes, despite solid 
evidence  that  the  pathway  itself  is  very  important 
to the biology of tumors.8–13 Thus, it is conceivable 
that the genes in the Notch signaling pathway may 
be regulated in trans by genetic variants located in 
genes in other biological pathways that crosstalk with 
the  Notch  signaling  pathway.  Therefore,  modeling 
gene regulatory networks using GWAS information, 
gene expression data and genes involved in the Notch 
signaling pathway provides the best mechanism for 
understanding  the  potential  molecular  mechanisms 
underlying Notch dysregulation in breast cancer.
Our group8 among others9,10 have shown that the 
Notch signaling pathway plays a critical role in the 
development  of  breast  cancer.  Numerous  cellular 
functions  and  microenvironment  cues  associated 
with  tumorigenesis  are  modulated  by  Notch  sig-
naling, including cell fate, proliferation, apoptosis, 
adhesion, and angiogenesis.11,12 Additionally, Notch 
signaling  plays  an  important  role  in  the  mainte-
nance of breast tumor-initiating cells.13 Of the four 
known Notch receptors, three have been implicated 
in breast   oncogenesis (Notch-1, -3, and -4) while one 
(Notch-2) has been suggested to have opposite roles 
and have a positive prognostic   significance.14 Notch-2 
has  recently  been  associated  with    ER-positive 
breast  cancer  tumors.15 Both  pan-Notch  inhibitors 
and specific monoclonal antibodies (mAb) to indi-
vidual  Notch  receptors  are  being  developed  for 
breast cancer. However, the molecular mechanisms 
underlying  dysregulation  and  aberrant  expression 
of Notch receptors and other genes involved in the 
Notch  signaling  pathway  leading  to  breast  cancer 
remain poorly understood. The association between 
the Notch signaling pathway and genes containing 
SNPs associated with risk for breast cancer could Association of gWAS information with the Notch signaling pathway
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provide putative functional bridges between GWAS 
  information with an   oncogenic   pathway that does not 
harbor mutations, but is involved in cancer develop-
ment and progression.8–13 Therefore, elucidating the 
association of GWAS information with the Notch sig-
naling pathway may help to determine which patients 
may benefit from Notch inhibitors and to explore the 
role of Notch transmembrane receptors as potential 
drug targets and predictive markers.
We hypothesized that genes containing SNPs with 
large (P # 10-5) and small to moderate (P∼10-2–10-4) 
effects associated with risk for breast cancer directly or 
indirectly interact with the 4 Notch family members, 
other genes in the Notch signaling pathway, and poten-
tially other biological pathways relevant to breast   cancer. 
To formally test this hypothesis, we mined data from 
41GWAS for SNPs and genes associated with risk for 
breast cancer, and two publicly available gene expres-
sion data sets derived from the Caucasian (42 cases and 
143 controls)16 and Asian (43 cases and 43 controls)17 
populations. Throughout this study, we have defined 
genes containing SNPs associated with risk for breast 
cancer as candidate genes, and assumed the gene and 
pathway as the units of association. We have assumed 
the P-value and correlation as measures of effect size 
for both GWAS and gene expression analysis.
Methods
Data sources
We mined the literature through PubMed searches and 
websites containing supplementary data on 41GWAS 
to identify SNPs and genes associated with risk for 
breast  cancer.  The  search  included  terms  (GWAS, 
GWA, WGAS, WGA,  genome-wide,  genomewide, 
whole genome, all terms + association, or + scan) 
in combination with breast cancer from the primary 
published reports through July 2010. All the reports 
were read and information was manually extracted 
and entered into the database. The inclusion   criterion 
was that the study must include a sample size of $500 
cases and $500 controls. We catalogued SNPs with 
large (P # 10-5) and small to moderate (P∼10-2–10-4) 
effect sizes. We chose this liberal statistical threshold 
to allow examination of genes containing borderline 
SNPs with small effect sizes and to include GWAS of 
various sizes accommodating publication bias while 
maintaining a consistent approach. SNPs   mapping to 
intergenic regions were not used in this study. SNP 
locations  and  gene  names  were  verified  using  the 
dbSNP  database  and  the  chromosome  report  build 
3.71. The Human Genome Nomenclature (HUGO) 
database was used to further check the authenticity of 
gene names and their aliases. The list of genes (gene 
symbols,  full  names),  number  of  SNPs  per  gene, 
along with references of primary reports from which 
the GWAS information was derived are summarized 
in Table A in the Appendix, provided as supplemen-
tary data to this manuscript.
We used two publicly available gene   expression 
data  sets  based  on  the  case  control  design  as  in 
GWAS design to evaluate and establish the expres-
sion levels of candidate genes and genes involved 
in  the  notch  signaling  pathway.  The  first  data  set 
involved  the    Caucasian  population,  and  consisted 
of 143 histologically normal breast tissues derived 
from patients harboring breast cancer who underwent 
curative mastectomy and 42 invasive ductal carci-
nomas of various histological grades obtained from 
breast cancer patients. The data set has been fully 
described by the originators.16 Briefly, this data set 
consisted of histological data.   Histologically-normal 
breast  has  the  potential  to  harbor  pre-malignant 
changes at the molecular level and thus provides a 
boon for identifying risk markers. We postulated that 
a   histologically-normal tissue with tumor-like gene 
expression patterns might harbor substantial risk for 
future  cancer  development.  Thus  genes  associated 
with these high-risk tissues would be considered to 
be  malignancy-risk  genes.  From  this  assumption, 
it follows that these genes could serve as potential 
molecular predictors of breast cancer. Normal breast 
cancer  tissue  included  histologically  normal  and 
benign. All samples were assessed for global gene 
expression profiles using the Affymetrix platform on 
U133 Plus 2.0 Array. The tumors were not associated 
with any known genetic risk factors such as BRCA1 
or BRCA2 mutations. The microarray data from these 
samples including the raw probe-level hybridization 
intensities were downloaded from the NCBI’s Gene 
Expression Omnibus (GEO) database under acces-
sion number GSE10780.
Most GWAS have been performed on   Caucasian 
populations.  It  remains  unclear  to  what  extent 
  findings  from  these  studies  can  be  extrapolated  to 
  non-Caucasians. To determine whether results found 
using  data  from  Caucasian  population  could  be hicks et al
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  replicated in the Asian population, we used a   second 
gene expression data set. The second data set involved 
a  multi-ethnic  Asian  population,  consisting  of 
  Malaysian breast cancer patients (Malays, Chinese and 
Indian). The data set has been described by.17 Briefly, 
the data set consisted of a total of 43 breast carcino-
mas and 43 patient-matched normal tissues collected 
from Kuala Lumpur, UKM and Putrajaya Hospitals in 
Malasia. The data set was generated using the Affyme-
trix platform’s U133A Chip and was downloaded from 
GEO accession number GSE15852. The two data sets 
contained similar information, both involved ductal 
carcinomas with same tumor grades. The clinical and 
histological characteristics of the two gene expression 
data sets used are summarized in Table 1.
In each of the two microarray data sets described 
above, entries in the data matrix were expression values 
generated by Affymetrix’s Microarray Analysis Suite 
5.0 (MAS5) statistical algorithm.18 Following normal-
ization and scaling, MAS5 signal values were summa-
rized by Turkey’s biweight estimation of the probe level 
intensities within each probe set. This was followed by 
a global normalization (linear scaling) to give all chips 
the  same  average  intensity.  These  procedures  yield 
robust  weighted  means  called  average-scaled  differ-
ences that are proportional to the amount of a particular 
RNA transcript present in the sample after background 
correction, which we used as the input in this analysis, 
after filtering out spiked control genes.
Data analysis
As a first step, we mapped SNPs to the genes by match-
ing gene names, SNP IDs and positions using the 
information in the database (dbSNP). We then sorted 
and ranked the genes on the basis of   P-values derived 
from GWAS, number of times the SNP in a particu-
lar gene has been replicated in multiple independent 
studies, and number of SNPs within each candidate 
gene. Genes containing SNPs with   P-values P # 10-5 
were considered to have large effect size, whereas 
genes containing SNPs with P-values P10-2–10-4 
were considered to have small to moderate effect size. 
Relatively few SNPs mapped to candidate genes had 
P-values sufficiently small (P # 10-5) or replicated in 
multiple independent studies to give conclusive evi-
dence of association.   Conversely, there were many 
genes containing several hundred SNPs with small to 
moderately significant P-values P∼10-2–10-4. These 
would likely contain several false positives, but may 
also  contain  genuine  effects  of  small  magnitude. 
Consequently,  in  our  data  analysis,  we  considered 
all the 150 candidate genes containing SNPs identi-
fied by GWAS. Our rationale was that, the presence 
of greater than expected number of associated SNPs 
in genes of similar biological functions interacting 
with each other and their downstream targets in bio-
logical pathways gives a degree of confidence that the 
associations are genuine, even if none is individually 
highly significant. The overall P-value for SNPs rep-
licated in multiple independent studies was estimated 
using Fisher’s method.19
Briefly, we assumed that the P-values (Pi) are inde-
pendent and uniformly distributed under their null 
hypotheses. Let Pi be the P-value for the correspond-
ing statistic Pi where [Pi = P1, P2, … Pn]T is a vec-
tor of P-values obtained by performing independent 
Table 1. Clinical and histological characteristics of Caucasian and Asian patients used in this study to generate gene 
  expression data.
eR, pR, Her2 and grade caucasian population Asian population
eR pR HeR2/neu eR pR HeR2/neu
Negative 25 38 43 18 17 22
Positive 55 42 12 25 26 21
Other 10 10 35 – – –
Total cases 90 90 90 43 43 43
Grade Frequency Frequency
Well differentiated or 1 6 8
Moderately differentiated or 2 27 24
Poorly differentiated or 3 57 11
Total cases 90 43Association of gWAS information with the Notch signaling pathway
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test statistic [Ti = T1, T2, … Tn]T on individual SNPs 
[rsi = rs1, rs2, … rsn]T. Assuming H as a continuous 
monotonic function, a transformation of the P-value 
can be defined as Zi = H-1(1 - Pi).20 The statistics for 
combining K independent P-values or for combining 
information from K SNPs is given by the following 
equation.20
 
ZZ i
i
K
=
= ∑
1
where,  Z  denotes  the  sum  of  Zi  (Z-scores)  of  the 
transformed P-values for the K SNPs. The Z-scores 
were back transformed into P-values using Fisher’s 
method.19
The challenge was how to represent a gene con-
taining  multiple  SNPs  within  the  gene  and  how 
to  account  for  correlations  among  those  SNPs. 
  Correlations among P-values of SNPs within a gene 
exist because of linkage disequilibrium among SNPs. 
Correlations among SNPs will invalidate the exist-
ing  methods  for  combining  independent    P-values. 
Furthermore,  the  SNPs  within  a  gene  may  have 
antagonistic functions which could not be captured 
by combining   P-values. Therefore, the method for 
combining P-values in independent SNPs described 
above  cannot  be  directly  applied  to  combining 
  P-values of SNPs within a gene. Wang et al,21 sug-
gested  choosing  the  most  significant  SNP  from 
each gene as a   representative. The limitation of that 
approach is that genes that contain a number of SNPs 
jointly having significant risk effects, but individu-
ally making only a small contribution, will be missed 
in such a representation. Therefore, in this study, we 
considered the gene and pathway containing SNPs 
as the units of association. This allowed us to holisti-
cally unravel the genetic susceptibility architecture 
of breast cancer by jointly considering all common 
variation within the gene and all the genes in the 
pathway through pathway prediction and modeling 
gene networks using candidate genes (ie, genes con-
taining SNPs associate with risk for breast cancer) 
and genes involved in the Notch signaling pathway.
Next, we matched the 150 candidate genes con-
taining SNPs along with genes involved in the Notch 
signaling pathway to probes on the U133 Plus 2.0 
Chips and U133A Human Chips,   representing gene 
expression from the Caucasian and Asian   populations, 
respectively.  The  probes  were  extracted  from  the 
NetAffx Database using the batch query (Affyme-
trix Inc). We then used probes to extract the gene 
expression values for the candidate genes and genes 
involved in the Notch signaling pathway from gene 
expression data sets on Caucasian and the Asian pop-
ulations, respectively.
On each data set containing candidate genes and 
genes involved in the Notch signaling pathway, we 
performed supervised analysis comparing mean gene 
expression profiles in cancer patients to mean gene 
expression profiles in cancer-free controls to identify 
significantly  differentially  expressed  genes,  which 
distinguished the two groups and were predictors of 
cancer, as demonstrated in Figures 1 and 2 for the 
Caucasian and Asian populations, respectively. We 
used the Benjamin and Hochberg22 procedure to cor-
rect for multiple testing. Genes were then ranked on 
estimated P-values and false discovery rate as shown 
in the Appendix Tables B and C for the Caucasians 
and Asians, respectively, and those passing a thresh-
old (P # 0.05) were selected. We performed correla-
tion analysis using Pearson correlation (r) coefficient 
procedure to identify genes with similar expression 
profiles, and to assess the association between candi-
date genes and genes involved in the Notch signaling 
pathway. In correlation analysis, genes were treated 
as the variables and their expression values as the 
measurements. The  correlation  coefficient  between 
the candidate gene X and Notchgene Y [and between 
candidate genes] was computed using the following 
equation.
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Figure 1. Distribution of mean expression values for candidate genes 
between breast cancer patients (y-axis) and normal subjects (x-axis) in 
the Caucasian population. Blue dots significantly deviating from the red 
line indicate differential expression. The genes, estimates of P-values 
and false discovery rates for each gene are presented in Table B in the 
Appendix provided as supplementary data.hicks et al
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where n is the sample size, Xi and Yj [X - and Y -] are 
the  expression  [mean]  expression  values  for  the 
candidate gene and the gene involved in the Notch 
signaling pathway, respectively. SX and SY are the 
standard deviations of the expression values for the 
candidate gene and the gene involved in the Notch 
signaling  pathway,  respectively.  Both  supervised 
and  correlation  analyses  were  performed  using 
GenePattern.23
Finally, we performed pathway prediction and net-
work modeling using the Osprey System24 to identify 
candidate genes which interact with genes involved 
in the Notch signaling pathway and other biologi-
cal pathways relevant to breast cancer. The Osprey 
network modeling and visualization system is a very 
dynamic software platform which integrates experi-
mental  information  from  the  literature  with  gene 
ontology information from the GO database about 
all the genes. Therefore, it allowed capturing all the 
genes that interact with the input genes (ie, candidate 
genes  and  genes  in  the  Notch  signaling  pathway) 
that  have  been  experimentally  confirmed  and  are 
involved in the same biological process, which may 
have been missed during differential expression and 
  co-expression analysis. Thus, is an optimal tool for 
pathway prediction, network modeling and in silico 
validation of predicted pathways and gene networks.
In pathway prediction and network visualization, 
we  first  performed  pathway  prediction  using  a  set 
of candidate genes containing SNPs associated with 
risk for breast cancer and members of the Notch sig-
naling pathway, which were differentially expressed 
between cases and controls in the Caucasian popu-
lation. We repeated the same analysis for the Asian 
population. To determine whether genes containing 
SNPs with larger effects and SNPs replicated in mul-
tiple independent studies interact with genes in the 
Notch  signaling  pathway,  we  performed  separate 
analysis for each set of genes. In pathway prediction, 
genes were represented by nodes and the interactions 
by vertices. Two genes were considered to share a 
genetic susceptibility architecture and network prop-
erties if they were interconnected as represented by 
the vertices and were correlated as determined by the 
correlation coefficient. To determine the functional 
relationships and biological properties of genes in the 
networks, we used the biological process category of 
the Gene Ontology classification built in the Osprey 
System to color-code the nodes (genes). We imposed 
level 3 filtering criteria to remove genes with spuri-
ous interactions, which could be less informative or 
could distort the reliability of network modeling. This 
approach also served as a validation step in that we 
randomly removed genes with fewer interactions and 
repeated the analysis.
Results
We investigated the association of GWAS informa-
tion with the Notch signaling pathway. GWAS infor-
mation  included  a  total  497  SNPs  associated  with 
risk for breast cancer. The SNPs were derived from 
41  GWAS,  totaling  more  than  250,000  cases  and 
250,000 controls, mostly (99%) from the Caucasian 
populations. From the total, 112 SNPs were located in 
intergenic regions and were not used in the   analysis. 
The remainder, 385 SNPs mapped to 150 genes, of 
which 130 candidate genes matched probes on the 
U133 Plus 2.0 Chip for data on Caucasian popula-
tion and 111 candidate genes matched probes on the 
U133A Chip for data on Asian population, and were 
used in the analysis. The discrepancy in the number 
of genes in the two data sets is due to differences 
in Chip density (ie, difference in probes and unique 
number of genes represented on the U133 Plus 2.0 
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Figure 2. Distribution of mean expression values for candidate genes 
between  breast  cancer  patients  (y-axis)  and  normal  subjects  (x-axis) 
in the Asian population. Blue dots significantly deviating from the red 
line indicate differential expression. The genes, estimates of P-values 
and false discovery rates for each gene are presented in Table C in the 
Appendix provided as supplementary data.Association of gWAS information with the Notch signaling pathway
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and U133A Human Chips). The list of gene symbols, 
SNP (rs_IDs), number of SNPs per gene along with 
the primary sources (ie, references) are provided as 
supplementary material in Table A in the   appendix. 
Genes  involved  in  the  Notch  signaling  pathway 
included the 4 members of the Notch family of trans-
membrane receptors, NOTCH1, NOTCH2, NOTCH3, 
NOTCH4 and other genes involved in Notch signal-
ing pathway including, PTEN, HES1, HES2, SKP2, 
DICER,  XIAP,  JAG1,  JAG2,  HES1,  HES2,  HEY1, 
HEY2, FBXW7, SKPIA, CCNA1, CCNA2, IAP, MYC, 
VEGFA, VEGFB, VEGFC and TP53, NUMB, DLL1, 
DLK2, DLL3 and DLL4. We hypothesized that genes 
containing SNPs associated with risk for breast can-
cer interact with the members of the Notch family of 
transmembrane receptors and other genes involved in 
the Notch signaling pathway and other pathways rel-
evant to breast cancer.
As a first step, we evaluated the expression of can-
didate genes and genes involved in the Notch signal-
ing pathway by comparing normal breast to breast 
tumors in Caucasian and Asian populations using 
publicly available gene expression data described in 
the methods section, as demonstrated in Figures 1 
and  2  for  the  Caucasian  and  Asian  populations, 
respectively. We sought to identify candidate genes 
and members of the Notch signaling pathway that 
were significantly differentially expressed between 
breast cancer and normal tissue. Such genes would 
serve as molecular predictors of breast cancer. We 
then  used  the  identified  differentially  expressed 
genes as the input for pathway prediction and net-
work modeling.
Using  supervised  analysis,  we  identified 
71    candidate  genes  and  12  genes  involved  in  the 
Notch signaling pathway, with significant differences 
in expression profiles between the cases and controls 
in the Caucasian population. The list of significantly 
differentially expressed genes involved in the Notch 
signaling pathways included HEY1 (P = 5.00E-06), 
HEY2 (P = 5.00E-06), JAG2 (P = 500E-06), MYC 
(P    0.002),  NOTCH1  (P  =  3.00E-05),  NOTCH2 
(P  =  2.00E-05),  NOTCH4  (P  =  5.00E-06),  SP2 
(P    0.04),  DICER1  (P    0.0004)  and  FBXW7 
(P = 5.00E-06). Repeating the same analysis using 
gene  expression  data  from  the  Asian  population, 
we identified 31 candidate genes and several genes 
involved  in  the  Notch  oncogenic  pathway  (PTEN, 
P5e-06; HEY2, P = 0.04; IAPP, P = 0.05) with sig-
nificant  differences  in  expression  profiles  between 
cases and controls. A full list of significantly differen-
tially expressed (and non significantly differentially 
expressed)  candidate  genes  between  breast  cancer 
patients and controls, their estimated P-values and 
false discovery rates for the Caucasian and Asian pop-
ulations are provided in Tables B and C, respectively, 
provided as supplementary data. As expected, not all 
candidate genes exhibited differences in expression 
profiles between cases and controls. In addition, not 
all  candidate  genes  differentially  expressed  in  the 
Caucasian population were replicated in the Asian 
population.
This  suggests  that  like  GWAS  results,  gene 
expression can be heterogeneous among populations, 
making it difficult to replicate results. The observed 
differences in expression profiles between cases and 
controls in the two populations can be attributed to 
several factors; including the fact that gene expres-
sion varies among populations,
25 differences in tissue 
procurement timing and storage, use of chips with 
different probe densities, as well as the genetic and 
phenotypic heterogeneity inherent in the GWAS data 
used in this study. Co-expression analysis however 
revealed that candidate genes that were not differ-
entially  expressed  exhibited  co-expression  patterns 
with sets of genes distinguishing cancer from normal 
controls.
To  formally  test  the  hypothesis  that  candidate 
genes containing SNPs associated with risk for breast 
cancer interact with genes involved in the Notch sig-
naling  pathway,  we  performed  pathway  prediction 
and   network modeling. As a first step, we performed 
pathway prediction and network modeling using the 
71 candidate genes confirmed in the Causation pop-
ulation and all genes involved in the Notch signal-
ing pathway. In addition we modeled the biological 
relationships of the genes in the predicted pathways 
and networks using Gene Ontology information and 
experimental information derived from the literature 
by text   mining using the module built in the Osprey 
System.  The  key  for  GO  information  characteriz-
ing genes in the predicted pathways and networks 
according  to  the  biological  process  in  which  they 
are involved is presented in Figure 3. The results of hicks et al
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pathway  prediction  and  network  modeling  for  the 
  Caucasian   population are presented in Figure 4. For 
easy interpretation throughout the figures, names of 
candidate genes (ie, genes containing SNPs associ-
ated with risk for breast cancer) are shown in red. 
Names of genes involved in the Notch signaling path-
way are shown in blue, while names of the new set 
of genes not identified by GWAS are shown in black. 
Nodes represent the genes and the vertices represent 
the interactions.
Members of the Notch family of transmembrane 
receptors NOTCH1, NOTCH2, were found to inter-
act with genes containing SNPs associated with risk 
for breast cancer (Fig. 4). Interactions were found 
between  NOTCH1  and  several  DNA  repair  genes, 
including XRCC6, XRCC5, and CHEK1; and between 
NOTCH2 and GSK3B, FANCA, MSH2. Also observed 
were  interactions  between  other  members  of  the 
Notch signaling pathway, for example, MYC, CNNA1, 
JAG1, FBXW7, CNNA2, XIAP, with genes containing 
SNPs associated with risk for breast cancer.
To evaluate the strength of association between 
candidate genes and the Notch signaling pathway in 
the Caucasian population we estimated correlations 
between pairs of genes. Focusing on candidate genes 
with  SNPs  replicated  in  multiple  GWAS  studies. 
Significant correlations (P  0.05) between Notch 
receptors and FGFR2 (NOTCH1, r = 0.20; NOTCH2, 
r = 0.37; NOTCH3, r = -0.23) were observed. Sig-
nificant correlations between other genes involved in 
the Notch signaling pathway and FGFR2 were also 
observed, including with (MYC, r = 0.27; DICER, 
r = 0.36; HEY1, r = 0.44; HEY2, r = 0.57; JAG2, 
r = 0.47). Other candidate genes which exhibited sig-
nificant correlations with genes involved in the Notch 
signaling pathway included (NOTCH1 versus PGR, 
r = -0.24; NOTCH4 versus PGR, r = -0.26; ESR1 
versus  SKP2,  r  =  -0.46;  FANCA  versus  FBXW7, 
r  =  -0.44;  ERBB2  versus  NOTCH3,  r  =  0.49; 
CDKN2A versus SKP2, r = 0.70; CDKN2A versus 
CHEK1, r = 0.68; CDKN2A   versus CHEK2, r = 0.55; 
DICER versus BLM, r = -0.56; HES1 versus BLM, 
r = 47; HES2 versus BLM, r = 52, FBXW7 versus 
CHEK2, r = -0.49; FBXW7 versus ERBB2, r = -0.41 
and NOTCH3 versus ERBB2, r = 0.49). This confirms 
our hypothesis that candidate genes are associated 
with Notch receptors and other genes involved in the 
Notch signaling pathway.   Supporting the validity of 
our observations, in addition to the Notch signaling 
pathway, we identified other biological pathways rel-
evant to breast cancer. Additional biological pathways 
enriched by SNPs and relevant to breast cancer iden-
tified in this analysis included the P53 pathway, the 
apoptosis control pathways, MAP kinase pathways, 
the estrogen receptor pathway and the insulin growth 
factor pathway.
In general, the interactions between candidate genes 
and Notch signaling appears to be complex involving 
multiple pathways, suggesting that multiple interact-
ing pathways are likely involved in the development 
and progression of breast cancer. The involvement 
of multiple pathways also indicates that interactions 
between the Notch signaling pathway and candidate 
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Figure 3. Color codes indicating the biological process in which genes 
reported in figures 4–7 are involved.Association of gWAS information with the Notch signaling pathway
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genes containing SNPs associated with risk for breast 
cancer may involve multi-pathway   crosstalk. A clear 
example was the involvement of NUMB, which is 
involved in the Notch signaling pathway but also con-
trols P53 tumor suppressor activity in breast cancer.26 
NUMB is a cell fate determinant, which by asym-
metrically partitioning at mitosis, controls cell fate 
choices by antagonizing the activity of the plasma 
membrane receptor of the Notch family.27
Of  particular  interest  were  the  three-way 
  interactions among genes containing SNPs with large 
(P # 10-5) and small to moderate (P∼10-2–10-4) effects 
and genes involved in the Notch signaling pathway; 
and  the  interactions  among  candidate  genes.  This 
indicates that the genetic susceptibility architecture of 
breast cancer is complex and that even genes contain-
ing SNPs with small effects often considered as noise 
in GWAS analysis could potentially have significant 
effects on development and progression of cancer. 
These  results  demonstrate  that  pathway  prediction 
and network modeling could potentially increase the 
power of GWAS analysis by taking into account com-
plex interactions which could not be realized using 
GWAS alone.
A  major  concern  in  genome-wide  association 
  studies is that majority of the GWAS studies ∼99% 
(based  on  this  study)  have  been  conducted  on 
  Caucasian populations. To determine whether results 
of pathway prediction and network modeling observed 
in the Caucasian population could be replicated in the 
Asian population, we performed pathway prediction 
using the 31 differentially expressed candidate genes 
Figure 4. results of pathway prediction and network modeling showing interactions between genes containing SNPs associated with risk for breast cancer 
and genes involved in the Notch signaling and other biological pathways based on the Caucasian population. Nodes represent genes and vertices rep-
resent interactions. The color code denotes the biological process in which the genes are involved as defined in Figure 3. The color codes in the vertices 
indicate the experimental techniques or a combination thereof used to confirm the relationship between the genes as determined by the experiments 
reported in the literature. Candidate genes containing SNPs associated with risk for breast cancer are shown in red, genes involved in the Notch signaling 
pathway are shown in blue and new genes not reported in gWAS studies are shown in black. For the full names of genes and number of SNPs per gene 
including gWAS references, please refer Table A in supplementary data.hicks et al
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identified using gene expression data derived from 
the Asian population and the set of genes involved 
in the Notch signaling pathway. The results showing 
pathway prediction and gene interaction networks for 
genes containing SNPs and members of the Notch 
signaling pathway based on the Asian population are 
presented in Figure 5. Genes involved in the Notch 
signaling pathway (NOTCH1, NOTCH2, NOTCH3, 
MYC,  HEY2,  FBXW7,  PTEN,  CCNA1,  CCNA1, 
JAG2, JAG1), were found to interact directly or indi-
rectly with genes containing SNPs associated with 
risk for breast cancer (ESR1, IGF1R, XRCC6, MGMT, 
CHEK1, MSH6, CDKN1A) (Fig. 5).
Like in the Caucasian population, genes contain-
ing SNPs associated with risk for breast cancer were 
also  found  to  be  associated  with  Notch  signaling, 
P53, apoptosis and MAP kinase pathways. To assess 
the strength of association between Notch receptors 
and candidate genes in the Asian population, we esti-
mated correlations. With the exception of NOTCH3 
(r = 0.15), all the Notch receptors were significantly 
(P  0.05) correlated with P53 (NOTCH1, r = 0.29; 
NOTCH2, r = 0.50; NOTCH4, r = 0.43). Significant 
correlations between the Notch receptors and IGF1-
were also observed (NOTCH1, r = 0.47; NOTCH2, 
r = 0.53; NOTCH4, r = 0.29). Similar results were 
found  between  Notch  receptors  and  the  IGF1R 
(NOTCH1, r = 0.27; NOTCH2, r = 0.60; NOTCH4, 
r  =  0.53)  and  between  Notch  receptors  and  the 
IGFBP3 (NOTCH1, r = 0.53; NOTCH2, r = 0.57; 
NOTCH3, r = 0.13; NOTCH4, r = 0.36). We also 
found  the  same  results  between  Notch  receptors 
and FYN (NOTCH1, r = 0.40; NOTCH2, r = 0.72; 
NOTCH3, r = 0.27; NOTCH4, r = 0.52). This con-
firms the association between candidate genes and the 
Notch signaling pathway. The P53, IGF1, IGFR1 and 
IGFBP3 and FYN genes have been reported in mul-
tiple independent GWAS studies. To the extent that 
these genes are also involved in different biological 
pathways,  these  results  indicate  crosstalk  between 
the Notch signaling pathway and the P53 and insu-
lin growth factor pathways. Additionally, significant 
correlations between IGF1 and PTEN (r = 0.65), and 
between PTEN and FYN (r = 0.61) were observed, 
Figure 5. results of pathway prediction and network modeling showing interactions between genes containing SNPs associated with risk for breast cancer 
and genes involved in the Notch signaling and other biological pathways based on the Asian population. Nodes represent genes and vertices represent 
interactions. The color code denotes the biological process in which the genes are involved as defined in Figure 3. The color codes in the vertices indicate 
the experimental techniques or a combination thereof used to confirm the relationship between the genes as determined by the experiments reported in 
the literature. Candidate genes containing SNPs associated with risk for breast cancer are shown in red, genes involved in the Notch signaling pathway 
are shown in blue and novel genes are shown in black.Association of gWAS information with the Notch signaling pathway
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yet another confirmation of association between the 
Notch signaling   pathway and candidate genes. PTEN 
is a major regulator of the Notch signaling pathway. 
In general, the biological pathways identified in the 
Caucasian population were replicated in the Asian 
populations. This  is  an    interesting  result  in  that  it 
demonstrates that although gene expression may vary 
across populations presumably due to environmental 
factors,  the  biological  pathways  underlying  breast 
cancer  development  and  progression  could  be  the 
same in different populations. Environmental factors 
were not considered in this study.
Both  the  validity  and  reproducibility  of  results 
from GWAS studies particularly the ones with small 
to  moderate  effect  sizes  (P∼10-2–10-4)  have  been 
challenged.28 Therefore, to determine whether genes 
involved  in  the  Notch  signaling  pathway  interact 
with  genes  that  contain  SNPs  with  good  evidence 
of association (ie, “winner” SNPs) (P # 10-5), we 
removed genes containing SNPs with small effects. 
We  then  repeated  pathway  prediction  combining 
genes involved in the Notch signaling pathways and 
genes containing SNPs with large effects. Genes con-
taining SNPs with larger effects (P # 10-5) included 
ABCC4, BTNL8, CASP8, COLIA1, ECHDC1, ESR1, 
FBN1, FGFR2, GRIK1, MLK4, LOC643714, LSP1, 
NEKIO,  PPP2R2B,  RAD51L1,  RFN146,  SLC4A7, 
TOX3, STXBP4, TGFB1, MAP3K1, H19. The results 
of genes containing SNPs with large effects are pre-
sented in Figure 6. We found that genes containing 
SNPs with large effects interact with each other and 
with genes involved in the Notch signaling pathway 
and other biological pathways involved in breast can-
cer. In addition, we also identified genes with small 
effects, for example, the IKBKB (P = 0.002).
To  further  address  the  problem  of  reliability  of 
GWAS data, we performed additional analyses com-
bining genes containing SNPs replicated in multiple 
independent studies with genes involved in the Notch 
Signaling pathway. Genes containing SNPs reported 
Figure 6. results of pathway prediction and network modeling showing interactions between genes containing SNPs associated with risk for breast cancer 
and genes involved in the Notch signaling and other biological pathways. The results are based on genes containing SNPs replicated in multiple indepen-
dent gWAS. Nodes represent genes and vertices represent interactions. The color code denotes the biological process in which the genes are involved as 
defined in Figure 3. The color codes in the vertices indicate the experimental techniques or a combination thereof used to confirm the relationship between 
the genes as determined by the experiments reported in the literature. Candidate genes containing SNPs associated with risk for breast cancer are shown 
in red, genes involved in the Notch signaling pathway are shown in blue and novel genes are shown in black.hicks et al
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in  multiple  independent  studies  included  A2BP1, 
ADH1B,  ALPL,  ATM,  BLM,  CASP8,  CCND1, 
CDKN1A, CHEK1, CSB, PMBT1, ECHDC1, EHMT, 
ERBB4,  ESR1,  FANCA,  FGFR2,  HCN1,  ICAM5, 
IGF1, IGFIR, IGFBP3, KU80, LSP1, MGMT, MSH2, 
NEIL2,  POLB,  POLK,  RAD51L1,  RB1,  RNF146, 
RPA1, RPA2, SKAP2, SOD2, MAP3K1, H19, TOX3, 
TGFB1,  TNP1,  XPA,  XPC,  XRCC3,  XRCC4.  The 
results are shown in Figure 7. We found that genes 
containing  SNPs  replicated  in  multiple  indepen-
dent studies interact with each other and with genes 
involved in the Notch signaling pathway, and genes 
involved  in  other  breast  cancer-relevant  biological 
pathways. In addition, we identified novel genes not 
yet identified by GWAS (genes shown in black).
To address the problem of publication bias and 
to determine whether members of the Notch signal-
ing pathway interact with candidate genes with small 
to moderate effects, we performed further analyses 
combining the genes involved in the Notch   signaling 
pathway and candidate genes containing SNPs with 
small effects. We found that genes containing SNPs 
with  small  effects  interact  with  genes  involved  in 
the Notch signaling pathway (results not presented 
because  we  captured  the  same  results  in  the  four 
figures reported above). In additional, we identified 
novel genes not reported in GWAS studies, including 
MDM2, CHUK, AR, WRN, XRCC6, ABL1, HDAC1 
and RAF1.
Overall,  in  all  the  analysis,  we  confirmed  our 
hypothesis  that  genes  containing  SNPs  associated 
with risk for breast cancer (regardless of effect size) 
interact with genes involved in the Notch signaling 
pathway as well as other biological pathways known 
to be relevant to breast cancer. Additionally, we iden-
tified novel genes not yet reported by GWAS. These 
Figure 7. results of pathway prediction and network modeling showing interactions between genes containing SNPs associated with risk for breast cancer 
and genes involved in the Notch signaling and other biological pathways. The results are based on genes containing SNPs with the largest effect size 
(P  10–5). Nodes represent genes and vertices represent interactions. The color code denotes the biological process in which the genes are involved as 
defined in Figure 3. The color codes in the vertices indicate the experimental techniques or a combination thereof used to confirm the relationship between 
the genes as determined by the experiments reported in the literature. Candidate genes containing SNPs associated with risk for breast cancer are shown 
in red, genes involved in the Notch signaling pathway are shown in blue and novel genes are shown in black.Association of gWAS information with the Notch signaling pathway
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results  demonstrated  that  GWAS  information  can 
be    leveraged  with  biological  knowledge  and  gene 
expression data to infer the association between gene 
expression and breast cancer. The association of the 
Notch oncogenic pathway with genes containing SNPs 
associated with risk for breast cancer demonstrates 
that integrative analysis combing GWAS information, 
gene expression data and biological knowledge is a 
powerful approach to identifying molecular markers 
underlying GWAS findings.
Discussion
In  this  study,  we  provide  evidence  of  association 
between breast cancer risk candidate genes and the 
Notch  signaling  pathway,  an  important  oncogenic 
pathway involved in many aspects of tumor devel-
opment,  growth  and  progression,  and  a  potential 
therapeutic target. Additionally, we identified other 
biological  pathways  including  the  ESR1  pathway, 
IGF pathway, the Map kinase pathway, the apopto-
sis pathway and the P53 pathway enriched by SNPs 
associated with risk for breast cancer. This suggests 
that regulation of the Notch pathway by candidate 
genes  from  GWAS  is  complicated  and  potentially 
involves  multi-dimensional  crosstalk  between  the 
Notch signaling pathway and other oncogenic path-
ways. Our results tend to agree with those in a recent 
association study, Fu et al,15 which showed the asso-
ciation between NOTCH2 and the P53 pathway in 
  ER-positive breast tumors.
Several  studies  have  now  attempted  pathway-
based approaches to dissect the genetic susceptibil-
ity architecture of common diseases, for example, in 
inflammatory diseases,29 in bipolar disorder,30 in mul-
tiple sclerosis,31 in breast cancer,32,33 prostate cancer,34 
and in seven common diseases.35 To our knowledge, 
this is the first study to associate GWAS information 
with the Notch signaling pathway. This is an impor-
tant finding because although GWAS as demonstrated 
in this and other studies2–6 can effectively map loci 
contributing to phenotypes of interest in breast can-
cer, they offer limited insights about the biological 
mechanisms by which SNPs confer risk. Of particu-
lar interest is the association of Notch signaling with 
multiple DNA repair genes including the XRCC5 and 
XRCC6,  which  participate  in  non-homologous  end 
joining for chromosomal DNA double-strand break 
repair, and they are essential for the efficient removal 
of  apurinic/apyrimidinic  sites  near  double-strand 
breaks.36 WRN, a member of the RecQ family of DNA 
helicases, interacts with XRCC5 and XRCC6 heterodi-
mers (also known as Ku70/80).37 WRN and the serine/
threonine protein kinase ATM, a master regulator of 
the  cellular  DNA  damage  response,  cooperatively 
participate in an intra-S checkpoint in cells with col-
lapsed  replication  forks.38  Protein  kinase  CHEK1 
participates  in  all  known  cell  cycle  checkpoints.39 
Checkpoint kinase 2 (CHEK2) is an important signal 
transducer of cellular responses to DNA damage, and 
it is considered a tumor suppressor; germ line defects 
of CHEK2 predispose to familial breast cancer and 
some other types of malignancies.40 FANCA partici-
pates in the repair of DNA interstrand crosslinks41 
and MSH2, a gene frequently mutated in familial non-
polylposis colon cancer,42 is a homolog of Drosophila 
MutS, a mismatch repair component.43
One possible explanation for these findings is that 
Notch  signaling  may  be  necessary  for  the  survival 
of cells that are deficient in DNA repair. Also, DNA 
repair  pathways  are  especially  active  in  cells  with 
stem-like  phenotypes,  potentially  including  tumor-
initiating cells.44,45 Interestingly, an increase in Notch 
activity is part of the response to radiation in breast 
cancer-initiating cells,46 endothelial cells47 and glioma 
stem cells.48
A number of genes involved in cell proliferation 
and survival are represented in our analysis. Among 
them, GSK3B is a protein kinase involved in glyco-
gen  metabolism  but  also  in  proliferation,  differen-
tiation and survival that is downstream of the Wnt 
and AKT pathways49. GSK3B itself, as well as the 
WNT  and  AKT  pathways  are  considered  potential 
therapeutic  targets  in  breast  cancer.50  Interestingly, 
Drosophila  Notch  is  known  to  interact  genetically 
with  the  homolog  of  GSK3B.51 Additional  interac-
tions  worth  noting  are  those  with  IKKα ( CHUK) 
and IKKβ (IKBKB). We have reported that Notch-1 
interacts and cooperates with IKKα in cervical52 and 
breast cancer cells,53 and Vilimas et al have shown 
that it interacts with the IKK signalosome in T-ALL 
cells.54 These findings emphasize the potential can-
cer relevance of the Notch-NF-κB cross-talk. Similar 
considerations can be made for Raf-1, a key mem-
ber of the Ras-Raf-MAP kinase pathway. We showed hicks et al
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in  2002  that  Ras-mediated  transformation  requires 
Notch-1.55 A number of cell cycle and proliferation-
related genes containing breast cancer-related SNPs 
also show   significant interaction with Notch pathway 
genes (eg, CDK2, CDC2, PCNA, cyclin E1), as does 
  multi-functional oncogene c-Myc, which is known 
to be a direct Notch target and genetically interact 
with  Notch-1  in  T-ALL.56  Protein  kinase  c-Abl  is 
another interesting Notch-interacting gene. In Droso-
phila, there is evidence of non-canonical interactions 
between Notch and Abl mediated by accessory protein 
Disabled.57 The anti-apoptotic mediator XIAP has been 
reported to physically interact with Notch-1, resulting 
in a direct interference with XIAP ubiquitination and 
degradation.58 Lipid phosphatase PTEN, which is fre-
quently defective in breast cancer, has been shown to 
be regulated by Notch in other models.59,60 Histone 
deacetylase 1 (HDAC1) is displaced by Notch dur-
ing  the  process  of    Notch-mediated  transcriptional 
  activation.61 We  have  recently  revealed  a  two-way 
feedback between Notch-1 and the estrogen recep-
tor alpha (ESR1) in breast cancer cells,8,53 as well as 
between Notch-1 and ERBB2.62
The  E3  ubiquitin  ligase  MDM2,  which  targets 
tumor protein p53 for proteasomal degradation, was 
identified in our analysis as a novel candidate in both 
Caucasian and Asian populations. In a mouse model, 
it has been shown that Notch suppresses p53 in lym-
phomagenesis through repression of the ARF-MDM2-
p53 tumor surveillance network.63 Interestingly, the 
endocytic protein NUMB, which is a negative regula-
tor of Notch activity, can be found in a complex with 
p53  and  MDM2,  thereby  preventing  ubiquitination 
and degradation of p53.26
Thus,  an  analysis  of  interactions  of  genes  that 
contain breast cancer-related SNPs with Notch path-
way genes reveals genes and gene products that have 
been suggested to cross-talk with Notch signaling 
in  other  models,  including  invertebrate  models,64 
supporting the validity of our approach. Moreover, 
this analysis detected additional candidates for func-
tional interactions with Notch, including numerous 
DNA  repair  and  checkpoint  genes,  the  androgen 
receptor  (AR),  free  radical  detoxifying  enzyme 
superoxide   dismutase 2 (SOD2) and other genes rel-
evant to breast carcinogenesis and to responsiveness 
to  therapeutic  agents  including  chemotherapeutics 
and    radiation.  The  association  between  the  Notch 
  signaling   pathway and GWAS information is impor-
tant in that numerous cellular functions and microen-
vironment  cues  associated  with  tumorigenesis  are 
modulated by Notch signaling, including prolifera-
tion,   apoptosis, adhesion, epithelial-to-mesenchymal 
transition  and  angiogenesis.11,64  Given  that  Notch 
signaling  is  activated  in  a  wide  variety  of  human 
breast cancer cases, components of the Notch path-
way have been evaluated as prognosis markers and 
drug targets.14 In breast cancer clinical specimens, 
mRNA  expression  of  Notch-1  and  Notch  ligand 
Jagged-1 have been shown to correlate strongly with 
poor prognosis.64–66 Loss of Notch-negative regula-
tor  NUMB,  has  been  described  in  approximately 
50%  of  human  breast  cancers.67  Notch-4  expres-
sion, as detected by immunohistochemistry, corre-
lates with Ki67, a well-known proliferation marker 
in infiltrating breast carcinomas of ductal or lobular 
  histologies.8  Conversely,  and  consistent  with  pub-
lished in vitro data, expression of Notch-2 appears to 
have a positive prognostic significance.68
Although the results of this study offer valuable 
clues about association of GWAS information with 
the Notch signaling pathway and other pathways rel-
evant to breast cancer, limitations in interpreting these 
results must be acknowledged. We have used results 
of  genome-wide  association  studies  and  publicly 
available gene expression data in this analysis. There-
fore, interpretation of our results is inherently subject 
to the constraints of such data. Key limitation include 
but are not limited to the fact that GWAS informa-
tion was derived from results obtained from different 
studies conducted using different platforms, sample 
sizes, cryptic population stratifications, different phe-
notypes, and potentially different analysis techniques 
all of which could potentially affect our results.
However, the results presented in this study dem-
onstrate  conclusively  that  genes  containing  SNPs 
associated with risk for breast cancer interact with 
genes involved in the Notch signaling pathway and 
other biological pathways relevant to breast cancer. 
Important work remains to be done to determine how 
the SNPs disrupt the genes and pathways, leading to 
cancer development and progression. Such work is 
beyond the scope of this paper, but the work reported 
here is the first step in that direction.Association of gWAS information with the Notch signaling pathway
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